On November 16, 2026, the Center for Medical Device Evaluation (CMDE) of China's National Medical Products Administration posted a notice dated November 12, 2026 that opens public comments on the draft Registration Review Guideline for Thrombus Aspiration Catheters, Part 1: Peripheral Thrombus Aspiration Catheters (血栓抽吸导管注册审查指导原则 第一部分 外周血栓抽吸导管(征求意见稿)). Chinese manufacturers of peripheral thrombus aspiration catheters filing a Class III NMPA registration, overseas manufacturers placing those catheters on the China market, domestic registration agents preparing Class III peripheral vascular intervention dossiers, and holders of an NMPA registration certificate for a peripheral thrombus aspiration catheter who plan a change filing must submit the CMDE feedback form by December 10, 2026, and align product technical requirements and clinical evaluation in any Class III registration or change dossier with the draft review points, or a comment sent after December 10, 2026 is outside this consultation, and a Class III dossier that does not meet the review points once the guideline is adopted can receive a CMDE deficiency or a refused registration certificate.

The draft is attachment 1 of the CMDE notice (draft text). The feedback form is attachment 2 (意见反馈表), sent to [email protected] (杨可馨, Yang Kexin, 021-68662293). Class III is China's highest medical-device risk class under State Council Order 739, and Class III devices, together with all imports, require central NMPA registration.

What does the November 16, 2026 notice open for comment?

CMDE states that it organized preparation of the Registration Review Guideline for Thrombus Aspiration Catheters, Part 1: Peripheral Thrombus Aspiration Catheters (draft for comments). After research and discussion, the centre has formed that draft as attachment 1 and, from the day of the notice, seeks comments on the web.

Comments and suggestions are made by filling in the feedback form (attachment 2) and sending it to the centre before December 10, 2026. The notice is signed by the NMPA Center for Medical Device Evaluation on November 12, 2026, and the page records a publication time of November 16, 2026. The same page gives the centre's address as 北京经济技术开发区广德大街22号院一区6号楼, postal code 100163, review-business telephone numbers 86452812 and 86452813, and an acceptance and electronic-filing number, 88331776.

Who must file the form or align a Class III dossier by December 10, 2026?

Chinese manufacturers filing a Class III registration for a peripheral thrombus aspiration catheter, overseas manufacturers placing that catheter on the China market, domestic registration agents preparing those Class III dossiers, and holders of an NMPA registration certificate who plan a change filing must submit the feedback form by December 10, 2026.

Under State Council Order No. 739, Class III devices and all imports are registered by the central NMPA, and CMDE evaluates the device. Obsidian tracks 3 regulatory texts, in force, amended or in preparation, under the CN Medical Device Regulation (Order 739) in China, as of November 2026. The notice is addressed to 各有关单位 (all relevant units). It does not name companies, and it does not itself adopt the guideline.

What should a commenter send before December 10, 2026?

The notice asks for comments and suggestions on the named draft, made on the feedback form (attachment 2) and returned to the centre before December 10, 2026. The notice page does not restate the draft's review points. Those points sit in attachment 1.

  • Download attachment 1, the draft guideline, and attachment 2, the feedback form, from the notice.
  • Write comments and suggestions on that draft in the feedback form.
  • Send the completed form to [email protected] before December 10, 2026.
  • Use the contact named on the notice, 杨可馨, telephone 021-68662293, for a question about how to file the form.
  • For a Class III registration or a change filing already in preparation, align product technical requirements and clinical evaluation with the draft review points in attachment 1.

What happens if the comment misses December 10, 2026?

A comment sent after December 10, 2026 is outside this consultation. Once the guideline is adopted, a Class III dossier that does not meet the review points can receive a CMDE deficiency or a refused registration certificate. In the China legislative steps recorded for this jurisdiction, public consultation (征求意见) sits before adoption, so the November 16, 2026 posting opens comments and does not itself put the draft into force.

Per-jurisdiction monitoring surfaces a CMDE consultation when the notice is posted, while the comment date is still the one in the notice.

Live
China NMPA medical devices: Order 739 implementation, registration and clinical evaluation rules
Monitor Chinese medical device regulation for the life sciences and medtech industry, for Swiss manufacturers registering devices in China.
Email 40+ news

Before December 10, 2026, download both attachments, file the form if a point in the draft should change, and brief the team that holds the Class III dossier so product technical requirements and clinical evaluation can be checked against attachment 1.